Fig. 1.

Low expression of BAP1 was correlated with better survival in ccRCC patients. (A) Analysis of genomic datasets from TCGA showed that about 90% of ccRCC patients do not harbor BAP1 mutation. (B) Lower BAP1 mRNA expression levels correlated with longer overall survival within patients carrying WT BAP1 (n = 133 each in low and high groups). (C) Schematic diagram of BAP1 engineering site for CRISPR-Cas9 and binding site for genotyping primers on genome. (D) The CRISPR-Cas9-derived mutations in 786-O BAP1-KO #1 and KO #2 cells were sequenced by Sanger sequencing. (E) Validation of endogenous BAP1 by Western blotting in BAP1 WT and KO cells. (F) Verifying the increase of ubiquitination on lysine119 of histone H2A by Western blotting.